BioLife Solutions (BioLife Solutions) ROCE % : -6.50% (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is BioLife Solutions ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BioLife Solutions's annualized ROCE % for the quarter that ended in Dec. 2023 was -6.50%.

BioLife Solutions ROCE % Historical Data

The historical data trend for BioLife Solutions's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLife Solutions ROCE % Chart

BioLife Solutions Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

1.20

-2.63

-8.39

-8.70

-14.82

BioLife Solutions Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															51.74	-13.13	-9.86	-29.96	-6.50

BioLife Solutions ROCE % Calculation

BioLife Solutions's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-57.533	/	( ( (450.229 - 44.582)	+	(412.714 - 42.178) )	/ 2 )
	=	-57.533	/	( (405.647	+	370.536)	/ 2 )
	=	-57.533	/	388.0915
	=	-14.82 %

BioLife Solutions's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-24.02	/	( ( (411.152 - 42.622)	+	(412.714 - 42.178) )	/ 2 )
	=	-24.02	/	( ( 368.53	+	370.536 )	/ 2 )
	=	-24.02	/	369.533
	=	-6.50 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

BioLife Solutions (NAS:BLFS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BioLife Solutions ROCE % Related Terms

Thank you for viewing the detailed overview of BioLife Solutions's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLife Solutions (BioLife Solutions) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioLife Solutions Inc (NAS:BLFS) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BJX1:Germany

Address

3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021

Website

https://www.biolifesolutions.com

BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs.

Executives

Geraint Phillips	officer: SVP, Global Operations	3303 MONTE VILLA, #310, BOTHELL WA 98021
Sarah Aebersold	officer: VP, Global Human Resources	BIOLIFE SOLUTIONS, INC., 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Troy Wichterman	officer: Chief Financial Officer	3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Greef Roderick De	director
Aby J. Mathew	officer: Chief Tech. Officer & Sr. VP	3303 MONTE VILLA PARKWAY, #310, BOTHELL WA 98021
Todd Berard	officer: Vice President, Marketing	3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Karen A. Foster	officer: Vice President of Operations	C/O BIOLIFE SOLUTIONS, INC., 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Michael Rice	director, officer: President & CEO	C/O BIOLIFE SOLUTIONS, INC., 171 FRONT STREET, OWEGO NY 13827
Casdin Partners Master Fund, L.p.	10 percent owner	WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Garrie Richardson	officer: Chief Revenue Officer	3303 MONTE VILA PARKWAY, BOTHELL WA 98021
Marcus Schulz	officer: Vice President, Global Sales	3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Joseph C Schick	director	16719 NE 139TH PLACE, WOODINVILLE WA 98072
Amy Duross	director	8410 GOLDEN BEAR PLACE, WHISTLER A1 V8E 1J7
Timothy L. Moore	director	C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Joydeep Goswami	director	SUMITOMO FUDOSAN MITA TWIN BLDG, EAST WING 4-2-8 SHIBAURA MINATO-KU, TOKYO M0 1080023